Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Mary Lynne Hedley, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan, with existing holdings of 1,524 shares held indirectly through a trust.

Summary

• Mary Lynne Hedley, a director at Eli Lilly & Co, acquired 11 shares of common stock on August 19, 2024, at a price of $921.81 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, where compensation is deferred as stock units.
• The shares will be settled in common stock after Ms. Hedley's separation from service.
• Ms. Hedley also indirectly owns 1,524 shares of Eli Lilly common stock through a trust.
• She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of a deferral plan aligns the director's interests with the long-term performance of the company.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and stock ownership, which is common in publicly traded companies.

Comparison to Industry Standards

• Director stock ownership and deferral plans are common practices among large pharmaceutical companies like Eli Lilly.
• These plans are designed to align the interests of directors with those of shareholders, similar to practices at companies like Pfizer and Merck.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it demonstrates director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Stock Acquisition, Deferral Plan, Common Stock, Beneficial Ownership, Lilly Directors' Deferral Plan